Research traces the evolution of a gene variant that reduces the risk of Alzheimer’s disease, finding that it originally evolved in response to infectious bacteria.
Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
Blocking activity of a kinase in a mouse model protects Golgi in cells and reduces the build-up of amyloid β, a primary component of Alzheimer’s disease.
The APOE4 variant causes cholesterol buildup in the cells that make protective fatty sheaths for neurons, possibly helping explain its role in neurodegeneration.